Can you discuss your experience with duvelisib in persons with the PTCL-TFH subtype and what range of response rates you have observed, as well as your deployment of duvelisib as bridge therapy for patients awaiting allograft stem cell transplant?

Name: Can you discuss your experience with duvelisib in persons with the PTCL-TFH subtype and what range of response rates you have observed, as well as your deployment of duvelisib as bridge therapy for patients awaiting allograft stem cell transplant?
Uploaded: 2025-08-19T00:00:00+00:00

CLICK HERE FOR CME CREDIT Back to Symposium

Created by

Presenter

Christina Poh, MD

Physician, Fred Hutchinson Cancer CenterAssistant Professor, Division of Hematology and OncologyUniversity of Washington School of MedicineSeattle, Washington